HLS Therapeutics Future Growth
Future criteria checks 1/6
HLS Therapeutics is forecast to grow earnings and revenue by 71.8% and 7.1% per annum respectively while EPS is expected to grow by 67.2% per annum.
Key information
71.8%
Earnings growth rate
67.2%
EPS growth rate
| Pharmaceuticals earnings growth | 53.0% |
| Revenue growth rate | 7.1% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 12 Nov 2024 |
Recent future growth updates
Recent updates
Are Investors Undervaluing HLS Therapeutics Inc. (TSE:HLS) By 45%?
Oct 26
Pinning Down HLS Therapeutics Inc.'s (TSE:HLS) P/S Is Difficult Right Now
Sep 28Analysts Have Lowered Expectations For HLS Therapeutics Inc. (TSE:HLS) After Its Latest Results
May 12After Leaping 29% HLS Therapeutics Inc. (TSE:HLS) Shares Are Not Flying Under The Radar
Apr 14Here's Why HLS Therapeutics (TSE:HLS) Can Afford Some Debt
Apr 06Analysts Are More Bearish On HLS Therapeutics Inc. (TSE:HLS) Than They Used To Be
Nov 16Here's Why HLS Therapeutics (TSE:HLS) Can Afford Some Debt
Sep 13Would HLS Therapeutics (TSE:HLS) Be Better Off With Less Debt?
May 05HLS Therapeutics (TSE:HLS) Is Due To Pay A Dividend Of $0.05
Apr 05HLS Therapeutics (TSE:HLS) Is Paying Out A Dividend Of $0.05
Mar 20HLS Therapeutics (TSE:HLS) Has Affirmed Its Dividend Of $0.05
Nov 30Downgrade: Here's How Analysts See HLS Therapeutics Inc. (TSE:HLS) Performing In The Near Term
Nov 11We Think HLS Therapeutics (TSE:HLS) Has A Fair Chunk Of Debt
Sep 14HLS Therapeutics (TSE:HLS) Is Due To Pay A Dividend Of $0.05
Aug 15HLS Therapeutics (TSE:HLS) Is Due To Pay A Dividend Of $0.05
Jul 14HLS Therapeutics (TSE:HLS) Has Announced A Dividend Of CA$0.05
Jun 23HLS Therapeutics' (TSE:HLS) Dividend Will Be CA$0.05
Jun 08HLS Therapeutics' (TSE:HLS) Dividend Will Be CA$0.05
May 25HLS Therapeutics' (TSE:HLS) Dividend Will Be CA$0.05
May 10Time To Worry? Analysts Are Downgrading Their HLS Therapeutics Inc. (TSE:HLS) Outlook
Apr 30HLS Therapeutics (TSE:HLS) Has Affirmed Its Dividend Of CA$0.05
Apr 15HLS Therapeutics (TSE:HLS) Has Re-Affirmed Its Dividend Of CA$0.05
Mar 26HLS Therapeutics Inc. (TSE:HLS) Analysts Just Slashed This Year's Estimates
Mar 22Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 62 | -7 | 17 | 17 | 5 |
| 12/31/2024 | 57 | -19 | 4 | 4 | 5 |
| 9/30/2024 | 57 | -22 | 22 | 9 | N/A |
| 6/30/2024 | 59 | -24 | 12 | 12 | N/A |
| 3/31/2024 | 61 | -28 | 12 | 13 | N/A |
| 12/31/2023 | 63 | -28 | 16 | 16 | N/A |
| 9/30/2023 | 63 | -29 | 15 | 16 | N/A |
| 6/30/2023 | 63 | -26 | 4 | 14 | N/A |
| 3/31/2023 | 62 | -26 | 5 | 15 | N/A |
| 12/31/2022 | 61 | -24 | 7 | 17 | N/A |
| 9/30/2022 | 61 | -21 | 7 | 17 | N/A |
| 6/30/2022 | 61 | -19 | 16 | 17 | N/A |
| 3/31/2022 | 60 | -12 | 12 | 15 | N/A |
| 12/31/2021 | 60 | -13 | 12 | 16 | N/A |
| 9/30/2021 | 61 | -16 | 11 | 18 | N/A |
| 6/30/2021 | 59 | -16 | -22 | 17 | N/A |
| 3/31/2021 | 57 | -20 | -28 | 11 | N/A |
| 12/31/2020 | 56 | -15 | -35 | 9 | N/A |
| 9/30/2020 | 54 | -20 | -41 | 6 | N/A |
| 6/30/2020 | 54 | -21 | -9 | 10 | N/A |
| 3/31/2020 | 55 | -16 | 4 | 23 | N/A |
| 12/31/2019 | 54 | -20 | 11 | 26 | N/A |
| 9/30/2019 | 57 | -7 | 11 | 35 | N/A |
| 6/30/2019 | 59 | -25 | 22 | 35 | N/A |
| 3/31/2019 | 61 | -24 | 14 | 28 | N/A |
| 12/31/2018 | 61 | -25 | 18 | 33 | N/A |
| 9/30/2018 | 65 | -26 | 28 | 30 | N/A |
| 6/30/2018 | 70 | -8 | N/A | 33 | N/A |
| 3/31/2018 | 73 | -8 | N/A | 37 | N/A |
| 12/31/2017 | 75 | -6 | N/A | 27 | N/A |
| 9/30/2017 | 71 | -11 | N/A | 25 | N/A |
| 12/31/2016 | 54 | -15 | N/A | 22 | N/A |
| 12/31/2015 | 20 | -10 | N/A | -6 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HLS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: HLS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: HLS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: HLS's revenue (7.1% per year) is forecast to grow faster than the Canadian market (7% per year).
High Growth Revenue: HLS's revenue (7.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if HLS's Return on Equity is forecast to be high in 3 years time